Gan & Lee Pharmaceuticals Co Ltd (603087.SS) is a biopharmaceutical company specializing in the research, development, production and commercialization of insulin analogs, active pharmaceutical ingredients and related medical devices for diabetes management. The company offers a portfolio of recombinant insulin products including Basalin (insulin glargine injection), Prandilin (insulin lispro injection), Prandilin 25 (insulin lispro mix 75/25), Rapilin (insulin aspart injection), Rapilin 30 (insulin aspart 30) and Similin 30 (insulin injection); insulin delivery devices such as GanleePen (insulin injection pen) and GanleeFine (insulin pen needle). Founded in 1998 and headquartered at No. 8 Nanfeng West 1st Street, Huoxian, Tongzhou District, Beijing, China, Gan & Lee operates primarily in the diabetes therapeutics segment with products registered in 23 countries, launched in 19 and under clinical trials in 10, targeting patients with type 1 and type 2 diabetes across China and international markets including Brazil, the US and Europe.
In recent developments, Gan & Lee signed a national Technology Transfer and Supply Agreement with Brazil's Fiocruz public laboratory, witnessed by the Brazilian Ministry of Health, to localize insulin manufacturing and accelerate market access; the company also entered a License and Supply Agreement with PC for the global rollout of its biweekly GLP-1 receptor agonist Bofanglutide (GZR18) in Latin America. Further advancing its pipeline, Gan & Lee initiated the US Phase 2 clinical trial of Bofanglutide (GZR18) injection for overweight or obesity patients following FDA IND clearance and dosed the first participant in Phase 3 GRADUAL-3 study in China; the US FDA accepted Biologics License Applications for insulin glargine, lispro and aspart injections, while GanleeFine pen needles received EMA GMP approval in 2024. The company ranked first in procurement demand for insulin analogs in China's 2024 National Insulin-Specific Centralized Procurement and appointed Dr. Ting JIA as Corporate Vice President and Chief Medical Officer to support global expansion of innovative drugs. Gan & Lee maintains GMP-compliant facilities including its Beijing recombinant human insulin production base and the under-construction Linyi Production Base, pursuing a dual strategy of innovation and globalization in metabolic diseases.